BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical's GHG Emissions Data Preview
In 2022, BioMarin Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).
However, BioMarin Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into BioMarin Pharmaceutical's Operational Emissions
In 2022, the total operational greenhouse gas (GHG) emissions of BioMarin Pharmaceutical amounted to 23,000 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
0BioMarin Pharmaceutical's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are BioMarin Pharmaceutical's Scope 1 emissions?
In 2022, the total Scope 1 emissions of BioMarin Pharmaceutical were 14,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has BioMarin Pharmaceutical reduced its Scope 1 emissions over time?
Since 2020, BioMarin Pharmaceutical's Scope 1 emissions have decreased by 6.67%, reflecting a declining long-term trend in Scope 1 emissions over time.
Compared to the previous year (2021), BioMarin Pharmaceutical's Scope 1 emissions decreased by 6.67%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.
What are BioMarin Pharmaceutical's Scope 2 emissions?
In 2022, BioMarin Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 9,000 tCOâ‚‚e using the location-based method.
Has BioMarin Pharmaceutical reduced its Scope 2 emissions over time?
Since 2020, BioMarin Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have increased by 28.57%, reflecting a rising long-term trend in Scope 2 emissions over time.
Compared to the previous year (2021), BioMarin Pharmaceutical's Scope 2 emissions (Location-Based) rose by 12.5% in 2022, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy
What methodology does BioMarin Pharmaceutical use for Scope 2 reporting?
In 2022, BioMarin Pharmaceutical reported its Scope 2 emissions using the location-based method.
BioMarin Pharmaceutical's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
Insights into BioMarin Pharmaceutical's Total Carbon Footprint
In 2022, BioMarin Pharmaceutical reported a total carbon footprint of 23,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 0% decrease compared to 2021, indicating progress in reducing its overall greenhouse gas output.
The largest contributor to BioMarin Pharmaceutical's total carbon footprint was Scope 1 emissions, accounting for 60.87% of the company's total carbon footprint, followed by Scope 2 emissions at 39.13%.